Expert Ratings for Health Catalyst
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ:HCAT) has received 4 analyst ratings in the last quarter, with 2 somewhat bullish and 2 indifferent, and no bullish or bearish ratings. The average 12-month price target among these analysts is $10.5, with a high of $12.00 and a low of $8.00. This target is a 22.22% decrease from the previous target of $13.50. Analyst ratings are updated quarterly and are based on financial analysis and company performance.

December 13, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Health Catalyst has an average analyst price target of $10.5, a decrease from the previous $13.50, with 2 somewhat bullish and 2 indifferent ratings in the last quarter.
The average price target for HCAT has decreased, indicating a more cautious view from analysts. However, there are no strongly bearish or bullish ratings, suggesting a neutral short-term impact on the stock price. The importance is high as price targets can influence investor expectations, but not at the maximum because the ratings are mixed and not extreme in either direction. The confidence level is high due to the clear data provided on analyst ratings and price targets.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100